Search Results for “biotechnology” – Page 13 – media

KCL study reveals particles in cows’ milk effective for oral delivery of RNA drugs

In a new study, researchers from King’s College London (KCL) have revealed that tiny particles present in cows’ milk could offer a new and effective method for the oral delivery of ribonucleic acid (RNA) drugs. Published in the Journal of Nanobiotechnology, the tiny particles known as extracellular vesicles (EV) could help protect and deliver RNA drugs following oral administration. RNA therapies are a powerful class of drugs based on nucleic acids that offer a way to target previously untreatable diseases on a molecular level. Despite successful administration via injection, there has been no successful way to deliver them orally, as the drugs are destroyed by the harsh conditions of the gut. Researchers extracted EVs from cows’ milk and loaded them with RNA molecules to treat inflammatory bowel disease (IBD). EVs are nanoscale transporters that carry biological molecules in a protective coat throughout the body, controlling and regulating the access of ...
- Source: drugdu
- 105
- May 1, 2024
Boehringer Ingelheim and Ochre Bio partner on liver disease in deal worth over $1bn

Chronic liver disease and associated cirrhosis account for one million deaths every year Boehringer Ingelheim and Ochre Bio have partnered to discover and develop novel, first-in-class regenerative treatments for chronic liver disease (CLD), including late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis. The partnership aligns with Boehringer’s drive to improve outcomes for patients living with interconnected cardiovascular, renal and metabolic diseases. Accounting for approximately one million deaths per year, CLD and associated cirrhosis cause significant morbidity, loss of health-related quality of life and economic burden. As CLD progresses, the liver’s natural ability to regenerate and repair diminishes, resulting in serious complications such as liver failure or liver cancer. Under the terms of the agreement, Ochre will receive up to $35m in upfront and near-term research-based milestone payments, as well as possible milestones for clinical, regulatory and commercial success plus tiered royalties, with an overall deal value with the potential to exceed $1bn. ...
- Source: drugdu
- 94
- April 25, 2024
BioPharma Expo 2024

Organiser: Reed Exhibitions Group Time:26 – 28 June 2024 address：3-21-1 Ariake, Koto-ku, Tokyo 135-0063, Japan Exhibition hall: Tokyo Big Sight International Exhibition Center Product range: Pharmaceutical raw materials and ingredients: pharmaceutical raw materials, apis, intermediates, additives, functional raw materials, natural extracts, fine chemicals, business outsourcing/processing /OEM, formulations, various analytical services and analytical equipment, and other raw materials, related services and technologies Biopharmaceutical: Laboratory equipment/reagents, biologics, drug development, biotechnology, genomics, etc About BioPharma Expo： The BioPharma Expo is Japan’s largest biopharmaceutical technology exhibition, covering research and development technology, manufacturing technology and contract services, with visitors, exhibitors and relevant people in the field of biopharmaceutical technology from all over the world.
- Source: drugdu
- 179
- April 25, 2024
GenFleet Therapeutics Announces FDA’s Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer

SHANGHAI, April 19, 2024 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a multi-center, open-label, randomized and controlled phase III study treating refractory metastatic colorectal cancer (CRC) patients. It is the first phase III trial of KRAS G12C inhibitor monotherapy targeting CRC patients worldwide, with GFH925 being the first G12C inhibitor that received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA) for previously treated advanced CRC. GFH925 was also granted BTD and New Drug Application acceptance with Priority Review Designation by NMPA for previously treated advanced non-small cell lung cancer（NSCLC）patients with G12C mutation. The trial (GFH925X0301) will enroll refractory metastatic CRC patients harboring KRAS G12C mutation who have progressed or experienced disease recurrence on or after at least two prior ...
- Source: drugdu
- 118
- April 24, 2024
Vietnam Medipharm Expo 2024

Organiser: Ministry of Health of Vietnam Time:1 – 3 August 2024 address：Lawrence S. Ting Building 801 Nguyen Van Linh Parkway, Dist. 7 Ho Chi Minh City Vietnam Exhibition hall: Saigon Exhibition & Convention Center Product range: Medical products: medical equipment and instruments, medical consumables, medical dressings, surgical equipment, rescue equipment, diagnostic equipment and supplies, ophthalmic equipment and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical health products and equipment, medical institutions and laboratory technical equipment, medical information and technical exchange, beauty equipment Analytical instruments: Optical analysis instruments, mass spectrometers, spectrometers, chromatographs, spectrometers, electrochemical analysis instruments, X-ray analysis instruments, gas chromatography, liquid chromatography, thermal analysis instruments, all kinds of portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, composition analysis instruments, injection analysis instruments and other general analytical instruments Laboratory equipment: Laboratory instruments and equipment, laboratory automation and accessories, optical instruments and equipment, ...
- Source: drugdu
- 143
- April 23, 2024
GlobalData

Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development. MASH innovator drugs witnessed over $2.5 billion increase in the total value of partnership deals from 2020 to 2024 year-to-date (YTD), with more than $2 billion forged in Q1 2024 alone, reveals GlobalData. MASH, previously known as nonalcoholic steatohepatitis (NASH), is a disease characteriSed by liver inflammation and damage caused by the accumulation of fat. Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), a small molecule THRB agonist, was the first drug approved by the FDA for MASH in March 2024. Alison Labya, Business Fundamentals Analyst at GlobalData, comments, “Interest in MASH has returned in light of the FDA approval of Madrigal’s Rezdiffra, as well as the success of GLP-1 obesity drugs and their potential efficacy in MASH, as demonstrated by Eli Lilly’s Zepbound (tirzepatide; also known as Mounjaro for type 2 diabetes) in its Phase II SYNERGY-NASH trial readout.” However, ...
- Source: drugdu
- 131
- April 20, 2024
ANKE Bio and SHIJIAN BIOLOGICAL enter into ADC platform technology licensing cooperation

Recently, Anhui ANKE Bio Engineering (Group) Co., Ltd (hereinafter referred to as “ANKE Bio”, stock code: 300009) signed a license agreement with Shanghai Shijian Biotechnology Co. (“ANKE Bio”). According to the license agreement, ANKE Bio has formally obtained the license of EZWi-Fit®, the ADC technology platform of SHIJIAN BIOLOGY, to develop ADC products. During the license period, ANKE Bio will be responsible for the preclinical research, clinical development and commercial production and sales of the developed products in Greater China, and will pay equity payments (including down payment and milestone payments) and a sales commission as a percentage of net sales to SHIJIAN BIO. Shijian Bio acquires an overseas interest in the ADC product. Shijian Bio is a clinical-stage ADC new drug discovery and development company with an ADC clinical pipeline and comprehensive new drug discovery and development capabilities, and has established a new-generation ADC technology platform, EZWi-Fit®, with its ...
- Source: drugdu
- 79
- April 19, 2024
YuanSong Bio-technology Receives Another Clinical Trial Approval, Its Innovative Lysoma Virus Product Receives Implied Clinical Trial Approval from China CDE

On April 12, 2024, Shanghai Yuansong Biotechnology Co., Ltd (“Yuansong Biotechnology”) announced that its self-developed lysosomal virus Class I new drug “Recombinant L-IFN Adenovirus Injection (YSCH-01)” has received implied clinical trial approval from the Center for Drug Evaluation of the State Drug Administration (CDE) and has been approved to conduct Class I clinical trials in China. The Center for Drug Evaluation (CDE) of the State Drug Administration has granted implied consent for clinical trials and approved to conduct Phase I clinical trials in China for the indication of advanced solid tumors. The approval of this IND filing by the CDE in China is another important progress made by YuanSong Biotech in exploring the clinical study of YSCH-01, in addition to the clinical approval by the US FDA in December 2023 for two original IIT programs under development, including capsular delivery for recurrent gliomas and lysosomal viral nebulized delivery for the ...
- Source: drugdu
- 148
- April 16, 2024
Sinovac Biotech Ltd.’s 5-dose Sabin Strain Inactivated Polio Vaccine Approved for Global Polio Eradication Efforts

On April 9, 2024, Beijing Sinovac Biotech Ltd., a subsidiary of Sinovac Holdings Biotechnology Ltd. (Sinovac Biotech), obtained the approval for registration of the 5-dose Sabin Strain Inactivated Polio Vaccine (Vero Cells) (hereinafter referred to as the 5-dose sIPV) developed by Sinovac Biotech Ltd. from the National Drug Administration (NDA) for the prevention of polio caused by the poliovirus types I, II and III. (hereinafter referred to as “sIPV”) received the approval of drug registration from the State Drug Administration (NMPA) for the prevention of poliomyelitis caused by poliovirus types I, II and III (commonly known as “polio”), and is suitable for the immunization of children aged 2 months and above. Compared with the single-dose sIPV vaccine, the 5-dose sIPV vaccine can significantly reduce the global immunization cost, and has been listed as an urgently needed variety in the WHO Polio Eradication Action Plan, and the launch of Sinovac Biotech ...
- Source: drugdu
- 130
- April 15, 2024
KOREA PHARM & BIO 2024

Organiser: KFDA、KPMA Time:23 – 26 April 2024 address：217-59 Kintekseu-ro, Daehwa-dong, Ilsanseo-gu, Goyang-si, Gyeonggi-do,Korea Exhibition hall: KINTEX Product range: Pharmaceutical: Pharmaceutical raw materials, API, pharmaceutical fine chemicals, intermediates, pharmaceutical additives, pharmaceutical agents, natural extracts, biotechnology, pharmaceutical outsourcing and services, laboratory equipment, pharmaceutical equipment, etc Chemical: chemical raw materials, chemical equipment, instrumentation, automatic control technology, heat exchanger, crystallization, gas absorption, drying, filtration, centrifuge, dust removal, chemical reactor, mill, blender, etc Cosmetics: cosmetic raw materials, cosmetic additives, functional materials, natural extracts, etc About KOREA PHARM & BIO： The KOREA PHARM & BIO event includes a variety of events, including a policy briefing on raw materials and pharmaceuticals, an export fair, and a variety of pharmaceutic-related seminars. The broad development space creates good opportunities for companies interested in exploring and developing the Korean market, and will undoubtedly become the best platform for companies to reach deals.
- Source: drugdu
- 170
- April 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.